Search results
- (-) Remove Press releases filter Press releases
Oxford BioMedica notes the CTL019 MAA submission to the EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
Oxford, UK – 06 November 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today not
Oxford BioMedica notes the CTL019 MAA submission to the EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
Oxford, UK – 06 November 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today not
Oxford BioMedica notes the primary analysis results from the pivotal JULIET trial demonstrating that Kymriah™ (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
Oxford, UK – 11 December 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene
Oxford BioMedica notes the US FDA Priority Review for Kymriah™ for adults with r/r DLBCL and EMA accelerated assessment for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
Oxford, UK – 17 January 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy
Oxford BioMedica announces £3 million grant awarded by Innovate UK
London, UK - 23 January 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy
Oxford BioMedica Announces Collaboration and Licence Agreement with Bioverativ in the Field of Haemophilia Gene Therapy
Oxford, UK– 15 February 2018: Oxford BioMedica plc (LSE:OXB) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy
Proposed placing to raise approximately £20.5 million
The following amendment has been made to the "PROPOSED PLACING TO RAISE APPROXIMATELY £20.5 MILLION" announcement released earlier today under RNS
Kymriah receives FDA approval to treat appropriate patients with large B-cell lymphoma
London, UK – 02 May 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy grou